Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01675479 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors

A NA study of Hyperopia, sponsored by Abbott Medical Optics.

Completed
Registry status
NA
Development phase
167
Enrollment target
9
Study locations

NCT01675479 is a NA study of Hyperopia that has completed, run by Abbott Medical Optics. The registered enrollment target is 167 participants, above the 108-participant average among 10 other Hyperopia trials with a reported enrollment target (55% higher). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01675479, a NA study of Hyperopia, has completed, sponsored by Abbott Medical Optics.

COMPLETED
Registry status
NA
Development phase
167 participants
Enrollment target
9
Study locations

Study Summary

Demonstrate that wavefront-guided LASIK using measurements from the iDesign System is safe and effective for the treatment of Hyperopia.

Conditions Studied

Interventions

  • DEVICE LASIK correction of hyperopic refractive errors

Study Locations (9)

Missouri

  • Pepose Vision Institute - Chesterfield
  • Durrie Vision - Kansas City

California

  • Maloney Vision Institute - Los Angeles

Florida

  • University of Miami Bascom Palmer Eye Institute - Miami

Illinois

  • Kraff Eye Institute - Chicago

New Mexico

  • Coleman Vision - Albuquerque

Texas

  • Lehmann Eye Center - Nacogdoches

Virginia

  • The Eye Center - Fairfax

Washington

  • King LASIK - Renton

Trial Details

FieldValue
Enrollment Target 167 participants
Start Date 2012-12-31
Est. Completion 2016-10-31
Phase NA

Sponsor

Abbott Medical Optics

14 total trials

What the Registry Record Tells You About NCT01675479

The ClinicalTrials.gov registry entry for NCT01675479 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 10 other Hyperopia trials with a reported enrollment target (55% higher). The listed sponsor is Abbott Medical Optics, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hyperopia appearing as the primary indexed condition, and to 1 intervention - of which LASIK correction of hyperopic refractive errors is the first listed.

NCT01675479 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Missouri, California, Florida.

Frequently Asked Questions

What is clinical trial NCT01675479 about?

NCT01675479 is a clinical study titled "Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors". Demonstrate that wavefront-guided LASIK using measurements from the iDesign System is safe and effective for the treatment of Hyperopia.

What is the current status of trial NCT01675479?

This trial is currently completed. It is a NA study. The enrollment target is 167 participants. The study started on 2012-12-31. Estimated completion is 2016-10-31.

What conditions does trial NCT01675479 study?

This clinical trial studies the following conditions: Hyperopia.

What interventions are being tested in trial NCT01675479?

The interventions under investigation include: LASIK correction of hyperopic refractive errors (DEVICE).

Who is sponsoring clinical trial NCT01675479?

This trial is sponsored by Abbott Medical Optics, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01675479 being conducted?

This trial has 9 study locations across California, Florida, Illinois, Missouri, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hyperopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.